CJC-1295 + Ipamorelin

The blend is supplied as a lyophilized (freeze-dried) white powder, typically with each peptide component at ≥98% purity as assessed by HPLC. The combined peptide mass per vial, individual component ratios, and lot-specific certificates of analysis (CoA) including mass spectrometry confirmation are available upon request to support research documentation requirements.

Published preclinical research on the individual components has utilized rat and pig pituitary cell primary cultures, GH3 pituitary cell lines, and rodent models. In vitro receptor pharmacology studies have used transfected HEK-293 cells expressing recombinant GHRHR or GHS-R1a. These systems are used to examine the receptor interactions of the individual components. The blend combines two peptides associated with distinct receptor pathways for laboratory research.

No. This product is supplied strictly for in vitro laboratory research and preclinical scientific investigation. It is not approved, intended, or suitable for human or veterinary clinical use, self-administration, dietary supplementation, or therapeutic application. All research use must comply with applicable institutional (IACUC, IRB) and regulatory guidelines governing research peptides.

CJC-1295 is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH) that acts as an agonist at the GHRH receptor (GHRHR), a Gs-coupled GPCR expressed on anterior pituitary somatotroph cells. Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the cognate receptor for ghrelin. The combination allows simultaneous research interrogation of both the GHRH-cAMP and ghrelin-Gq signaling axes in receptor pharmacology.